Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

被引:20
作者
Baek, Jong-Min [1 ]
Jin, Quanri [1 ]
Ensor, Joe [2 ]
Boulbes, Delphine R. [1 ]
Esteva, Francisco J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Breast cancer; Soluble CD44; HER2; Survival; NON-HODGKINS-LYMPHOMA; SOLUBLE CD44; COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; MESSENGER-RNA; COLON-CANCER; VARIANT; EXPRESSION; CARCINOMA; METASTASIS;
D O I
10.1007/s10549-011-1691-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD44 is an adhesion molecule involved in tumor cell invasion and metastasis. The function of CD44 in breast cancer is not understood completely, or is its role as a predictive or prognostic factor. In this study, we tested for the hypothesis that the concentration of soluble CD44 (sCD44) in serum is correlated with clinicopathological factors, especially HER2, and survival in patients with breast cancer. We retrospectively identified 110 patients with breast cancer who had been treated at The University of Texas MD Anderson Cancer Center (MDACC) from September 2001 to May 2004. Sera were collected before definitive surgery in patients with stage I or II breast cancer, before initiation of neoadjuvant chemotherapy (if indicated) for patients with stage I-III breast cancer, and before initiation of systemic therapy in patients with stage IV breast cancer. sCD44 levels were determined using an enzyme-linked immunosorbent assay. The median age at diagnosis was 51 years (range, 28.6-87.1 years). sCD44 concentration was correlated with tumor stage (P = 0.0308). sCD44 serum concentration did not predict pathological response in patients treated with neoadjuvant chemotherapy. Among patients with distant metastases, sCD44 levels were significantly higher in patients with liver involvement than in patients with metastases at other sites. The overall survival rate did not differ between patients with high sCD44 concentration and patients with low sCD44 concentration. However, sCD44 concentration was a significant predictor of overall survival for patients with HER2-positive breast cancer, while no difference in overall survival rates was observed in patients with HER2-negative breast cancer. To the best of our knowledge, this is the first study to show an association between circulating sCD44 levels and survival in HER2-positive breast cancer patients. Our results suggest a role for sCD44 as a prognostic marker. Furthermore, sCD44 level may offer a new clinical therapeutic target in HER2-positive breast cancer.
引用
收藏
页码:1029 / 1036
页数:8
相关论文
共 38 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: Soluble forms in relation to tumor tissue expression and metastasis [J].
Amirghofran Z. ;
Jalali S.A. ;
Hosseini S.V. ;
Vasei M. ;
Sabayan B. ;
Ghaderi A. .
Journal of Gastrointestinal Cancer, 2008, 39 (1-4) :73-78
[3]   Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas [J].
Berner, HS ;
Suo, Z ;
Risberg, B ;
Villman, K ;
Karlsson, MG ;
Nesland, JM .
HISTOPATHOLOGY, 2003, 42 (06) :546-554
[4]   Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: A multivariate analysis [J].
Bhatavdekar, JM ;
Patel, DD ;
Shah, NG ;
Vora, HH ;
Suthar, TP ;
Chikhlikar, PR ;
Ghosh, N ;
Trivedi, TI .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (04) :305-311
[5]   Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy [J].
Chang, S. M. ;
Xing, R. D. ;
Zhang, F. M. ;
Duan, Y. Q. .
ORAL DISEASES, 2009, 15 (08) :570-572
[6]  
Esteva Francisco J., 2001, Pathology and Oncology Research, V7, P171
[7]   Heparanase, hyaluronan, and CD44 in cancers:: A breast carcinoma perspective [J].
Gotte, Martin ;
Yip, George W. .
CANCER RESEARCH, 2006, 66 (21) :10233-10237
[8]   A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS [J].
GUNTHERT, U ;
HOFMANN, M ;
RUDY, W ;
REBER, S ;
ZOLLER, M ;
HAUSSMANN, I ;
MATZKU, S ;
WENZEL, A ;
PONTA, H ;
HERRLICH, P .
CELL, 1991, 65 (01) :13-24
[9]  
GUO YJ, 1994, CANCER RES, V54, P422
[10]   CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma [J].
Guriec, N ;
Marcellin, L ;
Gairard, B ;
Calderoli, H ;
Wilk, A ;
Renaud, R ;
Bergerat, JP ;
Oberling, F .
CLINICAL & EXPERIMENTAL METASTASIS, 1996, 14 (05) :434-439